The DOI matches its Crossref record; 121 of the 121 references it cites were found in a registry or an index.
Cytokines in the Treatment of Cancer
Open accessAbstract
Cytokines are major regulators of innate and adaptive immunity that enable cells of the immune system to communicate over short distances. Cytokine therapy to activate the immune system of cancer patients has been an important treatment modality and continues to be a key contributor to current clinical cancer research. Interferon alpha (IFNα) is approved for adjuvant treatment of completely resected high-risk melanoma patients and several refractory malignancies. High-dose interleukin-2 (HDIL-2) is approved for treatment of metastatic renal cell cancer and melanoma, but both agents are currently less commonly used with the development of newer agents. Granulocyte-macrophage colony-stimulating factor (GM-CSF), IFN gamma (IFNγ), IL-7, IL-12, and IL-21 were evaluated in clinical trials and remain part of certain investigational trials. The initial single-agent clinical trials with the long-awaited IL-15 have been completed and combination trials with antitumor antibodies or checkpoint inhibitors (CPIs) have been initiated. However, cytokines in monotherapy have not fulfilled the promise of efficacy seen in preclinical experiments. They are often associated with severe dose-limiting toxicities that are manageable with appropriate dosing and are now better understood to induce immune-suppressive humoral factors, suppressive cells, and cellular checkpoints, without consistently inducing a tumor-specific response. To circumvent these impediments, cytokines are being investigated clinically with new engineered cytokine mutants (superkines), chimeric antibody-cytokine fusion proteins (immunokines), anticancer vaccines, CPIs, and cancer-directed monoclonal antibodies to increase their antibody-dependent cellular cytotoxicity or sustain cellular responses and anticancer efficacy. In this review, we summarize current knowledge and clinical application of cytokines either as monotherapy or in combination with other biological agents. We emphasize a discussion of future directions for research on these cytokines, to bring them to fruition as major contributors for the treatment of metastatic malignancy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Darnell, J. E., Kerr, L. M., & Stark, G. R. (1994) · Science · doi:10.1126/science.8197455 · Cited by 6,080
Park, J.-H., Adoro, S., Guinter, T., Erman, B., Alag, A. S., Catalfamo, M., Kimura, M. Y., Cui, Y., Lucas, P. J., Gress, R. E., et al. (2010) · Nature Immunology · doi:10.1038/ni.1840 · Cited by 5,835
Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M., & Toda, M. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.3.1151 · Cited by 5,608
Interleukin-12 and the regulation of innate resistance and adaptive immunity
Trinchieri, G. (2003) · Nature Reviews Immunology · doi:10.1038/nri1001 · Cited by 3,927
Virus interference. I. the interferon
Isaacs, A., & Lindenmann, J. (1957) · Proceedings of the Royal Society of London. Series B - Biological Sciences · doi:10.1098/rspb.1957.0048 · Cited by 3,451
Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V, Hamada, H., Pardoll, D., & Mulligan, R. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3539 · Cited by 2,818
T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions
Schoenberger, S. P., Toes, R. E. M., van der Voort, E. I. H., Offringa, R., & Melief, C. J. M. (1998) · Nature · doi:10.1038/31002 · Cited by 2,615
Functional Role of Type I and Type II Interferons in Antiviral Defense
Müller, U., Steinhoff, U., Reis, L. F. L., Hemmi, S., Pavlovic, J., Zinkernagel, R. M., & Aguet, M. (1994) · Science · doi:10.1126/science.8009221 · Cited by 2,453
A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell
Ridge, J. P., Di Rosa, F., & Matzinger, P. (1998) · Nature · doi:10.1038/30989 · Cited by 2,342
Help for cytotoxic-T-cell responses is mediated by CD40 signalling
Bennett, S. R. M., Carbone, F. R., Karamalis, F., Flavell, R. A., Miller, J. F. A. P., & Heath, W. R. (1998) · Nature · doi:10.1038/30996 · Cited by 2,092
Atkins, M. B., Lotze, M. T., Dutcher, J. P., Fisher, R. I., Weiss, G., Margolin, K., Abrams, J., Sznol, M., Parkinson, D., Hawkins, M., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.7.2105 · Cited by 2,048
Rapid evolution of a protein in vitro by DNA shuffling
Stemmer, W. P. C. (1994) · Nature · doi:10.1038/370389a0 · Cited by 1,932
The role of interleukin-2 during homeostasis and activation of the immune system
Boyman, O., & Sprent, J. (2012) · Nature Reviews Immunology · doi:10.1038/nri3156 · Cited by 1,657
Reversible Defects in Natural Killer and Memory Cd8 T Cell Lineages in Interleukin 15–Deficient Mice
Kennedy, M. K., Glaccum, M., Brown, S. N., Butz, E. A., Viney, J. L., Embers, M., Matsuki, N., Charrier, K., Sedger, L., Willis, C. R., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.5.771 · Cited by 1,634
Kochenderfer, J. N., Dudley, M. E., Kassim, S. H., Somerville, R. P. T., Carpenter, R. O., Stetler-Stevenson, M., Yang, J. C., Phan, G. Q., Hughes, M. S., Sherry, R. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2025 · Cited by 1,595
Cytokines in cancer pathogenesis and cancer therapy
Dranoff, G. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1252 · Cited by 1,573
Fyfe, G., Fisher, R. I., Rosenberg, S. A., Sznol, M., Parkinson, D. R., & Louie, A. C. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.3.688 · Cited by 1,391
Yee, C., Thompson, J. A., Byrd, D., Riddell, S. R., Roche, P., Celis, E., & Greenberg, P. D. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.242600099 · Cited by 1,206
The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design
Waldmann, T. A. (2006) · Nature Reviews Immunology · doi:10.1038/nri1901 · Cited by 1,178
Self-citationNew insights into the regulation of T cells by γc family cytokines
Rochman, Y., Spolski, R., & Leonard, W. J. (2009) · Nature Reviews Immunology · doi:10.1038/nri2580 · Cited by 1,053
Experience with the Use of High-Dose Interleukin-2 in the Treatment of 652 Cancer Patients
ROSENBERG, S. A., LOTZE, M. T., YANG, J. C., AEBERSOLD, P. M., LINEHAN, W. M., SEIPP, C. A., & WHITE, D. E. (1989) · Annals of Surgery · doi:10.1097/00000658-198910000-00008 · Cited by 1,002
Romee, R., Rosario, M., Berrien-Elliott, M. M., Wagner, J. A., Jewell, B. A., Schappe, T., Leong, J. W., Abdel-Latif, S., Schneider, S. E., Willey, S., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf2341 · Cited by 942
IL-15Rα Recycles and Presents IL-15 In trans to Neighboring Cells
Dubois, S., Mariner, J., Waldmann, T. A., & Tagaya, Y. (2002) · Immunity · doi:10.1016/s1074-7613(02)00429-6 · Cited by 913
Self-citationSelective Stimulation of T Cell Subsets with Antibody-Cytokine Immune Complexes
Boyman, O., Kovar, M., Rubinstein, M. P., Surh, C. D., & Sprent, J. (2006) · Science · doi:10.1126/science.1122927 · Cited by 870
Improving the efficacy of antibody-based cancer therapies
Carter, P. (2001) · Nature Reviews Cancer · doi:10.1038/35101072 · Cited by 833
Leonard, J. P., Sherman, M. L., Fisher, G. L., Buchanan, L. J., Larsen, G., Atkins, M. B., Sosman, J. A., Dutcher, J. P., Vogelzang, N. J., & Ryan, J. L. (1997) · PubMed · Cited by 820
T-bet is rapidly induced by interferon-γ in lymphoid and myeloid cells
Lighvani, A. A., Frucht, D. M., Jankovic, D., Yamane, H., Aliberti, J., Hissong, B. D., Nguyen, B. V., Gadina, M., Sher, A., Paul, W. E., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.261570598 · Cited by 783
Antibody targeted drugs as cancer therapeutics
Schrama, D., Reisfeld, R. A., & Becker, J. C. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1957 · Cited by 768
The IL-2/IL-2 receptor system: A current overview
Taniguchi, T. (1993) · Cell · doi:10.1016/0092-8674(93)90152-g · Cited by 761
Liao, W., Lin, J.-X., & Leonard, W. J. (2011) · Current Opinion in Immunology · doi:10.1016/j.coi.2011.08.003 · Cited by 745
Conlon, K. C., Lugli, E., Welles, H. C., Rosenberg, S. A., Fojo, A. T., Morris, J. C., Fleisher, T. A., Dubois, S. P., Perera, L. P., Stewart, D. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.3329 · Cited by 711
Self-citationInterleukin-21: Basic Biology and Implications for Cancer and Autoimmunity
Spolski, R., & Leonard, W. J. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090316 · Cited by 696
Cytokines in Cancer Immunotherapy
Lee, S., & Margolin, K. (2011) · Cancers · doi:10.3390/cancers3043856 · Cited by 693
Senzer, N. N., Kaufman, H. L., Amatruda, T., Nemunaitis, M., Reid, T., Daniels, G., Gonzalez, R., Glaspy, J., Whitman, E., Harrington, K., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.3675 · Cited by 616
The Two Faces of Interferon-γ in Cancer
Zaidi, M. R., & Merlino, G. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0482 · Cited by 593
IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8 + T Cells
Klebanoff, C. A., Finkelstein, S. E., Surman, D. R., Lichtman, M. K., Gattinoni, L., Theoret, M. R., Grewal, N., Spiess, P. J., Antony, P. A., Palmer, D. C., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307298101 · Cited by 577
Self-citationExploiting a natural conformational switch to engineer an interleukin-2 ‘superkine’
Levin, A. M., Bates, D. L., Ring, A. M., Krieg, C., Lin, J. T., Su, L., Moraga, I., Raeber, M. E., Bowman, G. R., Novick, P., et al. (2012) · Nature · doi:10.1038/nature10975 · Cited by 552
Interleukin-21: a double-edged sword with therapeutic potential
Spolski, R., & Leonard, W. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4296 · Cited by 548
Jonasch, E., & Haluska, F. G. (2001) · The Oncologist · doi:10.1634/theoncologist.6-1-34 · Cited by 518
GUTTERMAN, J. U., BLUMENSCHEIN, G. R., ALEXANIAN, R., YAP, H.-Y., BUZDAR, A. U., CABANILLAS, F., HORTOBAGYI, G. N., HERSH, E. M., RASMUSSEN, S. L., HARMON, M., et al. (1980) · Annals of Internal Medicine · doi:10.7326/0003-4819-93-3-399 · Cited by 497
Interleukin 12: still a promising candidate for tumor immunotherapy?
Lasek, W., Zagożdżon, R., & Jakobisiak, M. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1523-1 · Cited by 495
Structure of the Quaternary Complex of Interleukin-2 with Its α, ß, and γ c Receptors
Wang, X., Rickert, M., & Garcia, K. C. (2005) · Science · doi:10.1126/science.1117893 · Cited by 475
IFN-γ production by antigen-presenting cells: mechanisms emerge
Frucht, D. M., Fukao, T., Bogdan, C., Schindler, H., O'Shea, J. J., & Koyasu, S. (2001) · Trends in Immunology · doi:10.1016/s1471-4906(01)02005-1 · Cited by 461
Waldmann, T. A. (1986) · Science · doi:10.1126/science.3008337 · Cited by 453
Self-citationRosenberg, S. A., Sportès, C., Ahmadzadeh, M., Fry, T. J., Ngo, L. T., Schwarz, S. L., Stetler-Stevenson, M., Morton, K. E., Mavroukakis, S. A., Morre, M., et al. (2006) · Journal of Immunotherapy · doi:10.1097/01.cji.0000210386.55951.c2 · Cited by 443
Coughlin, C. M., Salhany, K. E., Wysocka, M., Aruga, E., Kurzawa, H., Chang, A. E., Hunter, C. A., Fox, J. C., Trinchieri, G., & Lee, W. M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1555 · Cited by 415
Suppression of Lymphoma and Epithelial Malignancies Effected by Interferon γ
Street, S. E. A., Trapani, J. A., MacGregor, D., & Smyth, M. J. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020063 · Cited by 375
Bazarbachi, A., Plumelle, Y., Carlos Ramos, J., Tortevoye, P., Otrock, Z., Taylor, G., Gessain, A., Harrington, W., Panelatti, G., & Hermine, O. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.0669 · Cited by 373
Interleukin-15 biology and its therapeutic implications in cancer
Steel, J. C., Waldmann, T. A., & Morris, J. C. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2011.09.004 · Cited by 361
Self-citationInterferons in the treatment of human cancer.
Kirkwood, J. M., & Ernstoff, M. S. (1984) · Journal of Clinical Oncology · doi:10.1200/jco.1984.2.4.336 · Cited by 332
Mortier, E., Quéméner, A., Vusio, P., Lorenzen, I., Boublik, Y., Grötzinger, J., Plet, A., & Jacques, Y. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m508624200 · Cited by 308
Insights into Cytokine–Receptor Interactions from Cytokine Engineering
Spangler, J. B., Moraga, I., Mendoza, J. L., & Garcia, K. C. (2015) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120211 · Cited by 304
Carnemolla, B., Borsi, L., Balza, E., Castellani, P., Meazza, R., Berndt, A., Ferrini, S., Kosmehl, H., Neri, D., & Zardi, L. (2002) · Blood · doi:10.1182/blood.v99.5.1659 · Cited by 296
Gollob, J., Mier, J. W., Veenstra, K. G., McDermott, D. F., Clancy, D., Clancy, M., & Atkins, M. B. (2000) · PubMed · Cited by 285
Interleukin-2 and interleukin-15: immunotherapy for cancer
Fehniger, T. A., Cooper, M. A., & Caligiuri, M. A. (2002) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(01)00021-1 · Cited by 280
Lu, Y.-C., Parker, L. L., Lu, T., Zheng, Z., Toomey, M. A., White, D. E., Yao, X., Li, Y. F., Robbins, P. F., Feldman, S. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.5463 · Cited by 279
Treatment of hairy cell leukemia with recombinant alpha-interferon
Quesada, Jr., Hersh, E., Manning, J., Reuben, J., Keating, M., Schnipper, E., Itri, L., & Gutterman, J. (1986) · Blood · doi:10.1182/blood.v68.2.493.493 · Cited by 278
The IL-2 cytokine family in cancer immunotherapy
Sim, G. C., & Radvanyi, L. (2014) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2014.07.018 · Cited by 278
Caligiuri, M. A., Murray, C., Robertson, M. J., Wang, E., Cochran, K., Cameron, C., Schow, P., Ross, M. E., Klumpp, T. R., & Soiffer, R. J. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116161 · Cited by 269
Junghans, R. P., Ma, Q., Rathore, R., Gomes, E. M., Bais, A. J., Lo, A. S. Y., Abedi, M., Davies, R. A., Cabral, H. J., Al‐Homsi, A. S., et al. (2016) · The Prostate · doi:10.1002/pros.23214 · Cited by 267
Safety and immunologic effects of IL-15 administration in nonhuman primates
Berger, C., Berger, M., Hackman, R. C., Gough, M., Elliott, C., Jensen, M. C., & Riddell, S. R. (2009) · Blood · doi:10.1182/blood-2008-12-189266 · Cited by 244
Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial
Windbichler, G. H., Hausmaninger, H., Stummvoll, W., Graf, A. H., Kainz, C., Lahodny, J., Denison, U., Müller-Holzner, E., & Marth, C. (2000) · British Journal of Cancer · doi:10.1054/bjoc.1999.1053 · Cited by 241
Waldmann, T. A. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0009 · Cited by 238
Self-citationFloros, T., & Tarhini, A. A. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.05.015 · Cited by 229
Sportès, C., Babb, R. R., Krumlauf, M. C., Hakim, F. T., Steinberg, S. M., Chow, C. K., Brown, M. R., Fleisher, T. A., Noel, P., Maric, I., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1303 · Cited by 227
In vivo antitumor activity of interleukin 21 mediated by natural killer cells.
Wang, G., Tschoi, M., Spolski, R. J., Lou, Y., Ozaki, K., Feng, C., Kim, G., Leonard, W. J., & Hwu, P. (2003) · PubMed · Cited by 221
Yu, P., Steel, J. C., Zhang, M., Morris, J. C., & Waldmann, T. A. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1966 · Cited by 213
Self-citationCurrent status of granulocyte–macrophage colony-stimulating factor in the immunotherapy of melanoma
Kaufman, H. L., Ruby, C. E., Hughes, T., & Slingluff, C. L. (2014) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-2-11 · Cited by 212
Dubois, S., Patel, H. J., Zhang, M., Waldmann, T. A., & Müller, J. R. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.4.2099 · Cited by 205
Self-citationWaldmann, T. A., Lugli, E., Roederer, M., Perera, L. P., Smedley, J. V., Macallister, R. P., Goldman, C. K., Bryant, B. R., Decker, J. M., Fleisher, T. A., et al. (2011) · Blood · doi:10.1182/blood-2010-10-311456 · Cited by 195
Self-citationFas and the art of lymphocyte maintenance.
Lenardo, M. J. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.3.721 · Cited by 192
Bamford, R. N., DeFilippis, A. P., Azimi, N., Kurys, G., & Waldmann, T. A. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.9.4418 · Cited by 189
Self-citationInterleukin-2 Activity Can Be Fine Tuned with Engineered Receptor Signaling Clamps
Mitra, S., Ring, A. M., Amarnath, S., Spangler, J. B., Li, P., Ju, W., Fischer, S., Oh, J., Spolski, R., Weiskopf, K., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.04.018 · Cited by 175
Self-citationSandau, M. M., Schluns, K. S., Lefrancois, L., & Jameson, S. C. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.11.6537 · Cited by 175
Disorders of the JAK/STAT Pathway in T Cell Lymphoma Pathogenesis: Implications for Immunotherapy
Waldmann, T. A., & Chen, J. (2017) · Annual Review of Immunology · doi:10.1146/annurev-immunol-110416-120628 · Cited by 171
Self-citationMa, H.-L., Whitters, M. J., Konz, R. F., Senices, M., Young, D. A., Grusby, M. J., Collins, M., & Dunussi-Joannopoulos, K. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.2.608 · Cited by 162
Treatment of hairy cell leukemia with recombinant alpha 2 interferon
Ratain, M., Golomb, H., Vardiman, J., Vokes, E., Jacobs, R., & Daly, K. (1985) · Blood · doi:10.1182/blood.v65.3.644.644 · Cited by 161
The immunocytokine NHS-IL12 as a potential cancer therapeutic
Fallon, J., Tighe, R., Kradjian, G., Guzman, W., Bernhardt, A., Neuteboom, B., Lan, Y., Sabzevari, H., Schlom, J., & Greiner, J. W. (2014) · Oncotarget · doi:10.18632/oncotarget.1853 · Cited by 160
Tarhini, A. A., Cherian, J., Moschos, S. J., Tawbi, H. A., Shuai, Y., Gooding, W. E., Sander, C., & Kirkwood, J. M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.5394 · Cited by 160
Novel Human Interleukin-15 Agonists
Zhu, X., Marcus, W. D., Xu, W. V., Lee, H.-I., Han, K., Egan, J. O., Yovandich, J. L., Rhode, P. R., & Wong, H. C. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901244 · Cited by 155
Zhang, M., Yao, Z., Dubois, S. P., Ju, W., Müller, J. R., & Waldmann, T. A. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0902637106 · Cited by 144
Self-citationDevelopment and proliferation of lymphocytes in mice deficient for both interleukins‐2 and ‐4
Sadlack, B., Kühn, R., Schorle, H., Rajewsky, K., Müller, W., & Horak, I. D. (1994) · European Journal of Immunology · doi:10.1002/eji.1830240144 · Cited by 136
Out-of-Sequence Signal 3 Paralyzes Primary CD4+ T-Cell-Dependent Immunity
Sckisel, G. D., Bouchlaka, M. N., Monjazeb, A. M., Crittenden, M. R., Curti, B. D., Wilkins, D. E. C., Alderson, K. L., Sungur, C. M., Ames, E., Mirsoian, A., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.06.023 · Cited by 133
Tinhofer, I., Marschitz, I., Henn, T., Egle, A., & Greil, R. (2000) · Blood · doi:10.1182/blood.v95.2.610 · Cited by 131
Transient and persistent effects of IL-15 on lymphocyte homeostasis in nonhuman primates
Lugli, E., Goldman, C. K., Perera, L. P., Smedley, J. V., Pung, R., Yovandich, J. L., Creekmore, S. P., Waldmann, T. A., & Roederer, M. (2010) · Blood · doi:10.1182/blood-2010-03-275438 · Cited by 127
Self-citationYu, P., Steel, J. C., Zhang, M., Morris, J. C., Waitz, R., Fassò, M., Allison, J. P., & Waldmann, T. A. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1203479109 · Cited by 126
Self-citationMueller, Y. M., Petrovas, C., Bojczuk, P. M., Dimitriou, I. D., Beer, B., Silvera, P. M., Villinger, F. J., Cairns, J. S., Gracely, E. J., Lewis, M. G., et al. (2005) · Journal of Virology · doi:10.1128/jvi.79.8.4877-4885.2005 · Cited by 119
Jiang, S.-S., Tang, Y., Zhang, Y., Weng, D., Zhou, Z., Pan, K., Pan, Q., Wang, Q.-J., Liu, Q., He, J., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5463 · Cited by 115
Cytokine-secreting tumor cell vaccines
Mach, N., & Dranoff, G. (2000) · Current Opinion in Immunology · doi:10.1016/s0952-7915(00)00144-8 · Cited by 115
Chertova, E. N., Bergamaschi, C., Chertov, O., Sowder, R. C., Bear, J., Roser, J. D., Beach, R. K., Lifson, J. D., Felber, B. K., & Pavlakis, G. N. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.461756 · Cited by 113
Pettit, D. K., Bonnert, T. P., Eisenman, J. R., Srinivasan, S., Paxton, R., Beers, C., Lynch, D., Miller, B., Yost, J., Grabstein, K. H., et al. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.4.2312 · Cited by 113
Modulating T‐cell homeostasis with IL‐7: preclinical and clinical studies
Capitini, C. M., Chisti, A. A., & Mackall, C. L. (2009) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2009.02085.x · Cited by 110
Interleukin 21: combination strategies for cancer therapy
Skak, K., Kragh, M., Hausman, D. F., Smyth, M. J., & Sivakumar, P. V. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2482 · Cited by 110
Constantinescu, S. N., Croze, E., Wang, C., Murti, A., Basu, L., Mullersman, J. E., & Pfeffer, L. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.20.9602 · Cited by 108
Potential mechanisms of human natural killer cell expansion in vivo during low-dose IL-2 therapy
Fehniger, T. A., Bluman, E. M., Porter, M. M., Mrózek, E., Cooper, M. A., VanDeusen, J. B., Frankel, S. R., Stock, W., & Caligiuri, M. A. (2000) · Journal of Clinical Investigation · doi:10.1172/jci6218 · Cited by 106
The Role of Interferon in Cancer Therapy: A Current Perspective
Goldstein, D., & László, J. (1988) · CA A Cancer Journal for Clinicians · doi:10.3322/canjclin.38.5.258 · Cited by 105
Becker, J. C., Varki, N. M., Gillies, S. D., Furukawa, K., & Reisfeld, R. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.15.7826 · Cited by 104
Evans, R., Fuller, J. A., Christianson, G. J., Krupke, D. M., & Troutt, A. B. (1997) · Cellular Immunology · doi:10.1006/cimm.1997.1132 · Cited by 102
Sneller, M. C., Kopp, W. C., Engelke, K. J., Yovandich, J. L., Creekmore, S. P., Waldmann, T. A., & Lane, H. C. (2011) · Blood · doi:10.1182/blood-2011-09-377804 · Cited by 100
Self-citationJinushi, M., Hodi, F. S., & Dranoff, G. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00618.x · Cited by 91
Steele, N. L., Anthony, A., Saunders, M. P., Esmarck, B., Ehrnrooth, E., Kristjansen, P. E. G., Nihlén, A., Hansen, L. T., & Cassidy, J. (2012) · British Journal of Cancer · doi:10.1038/bjc.2011.599 · Cited by 88
Immunomodulatory Cytokines as Therapeutic Agents for Melanoma
Nicholas, C., & Lesinski, G. B. (2011) · Immunotherapy · doi:10.2217/imt.11.45 · Cited by 87
Immunotherapy of melanoma: Present options and future promises
Rotte, A., Bhandaru, M., Zhou, Y., & McElwee, K. J. (2015) · Cancer and Metastasis Reviews · doi:10.1007/s10555-014-9542-0 · Cited by 82
Antibody–cytokine fusion proteins for the therapy of cancer
Penichet, M. L., & Morrison, S. L. (2001) · Journal of Immunological Methods · doi:10.1016/s0022-1759(00)00345-8 · Cited by 80
Moga, E., Álvarez, E., Cantó, E., Vidal, S., Rodríguez-Sánchez, J. L., Sierra, J., & Briones, J. (2007) · Experimental Hematology · doi:10.1016/j.exphem.2007.08.012 · Cited by 71
Tumor infiltrating lymphocyte therapy for ovarian cancer and renal cell carcinoma
Andersen, R. S., Donia, M., Westergaard, M. C. W., Pedersen, M., Hansen, M., & Svane, I. M. (2015) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1075106 · Cited by 68
Increased serum soluble IL-15Rα levels in T-cell large granular lymphocyte leukemia
Chen, J., Petrus, M., Bamford, R. N., Shih, J. H., Morris, J. C., Janik, J. E., & Waldmann, T. A. (2011) · Blood · doi:10.1182/blood-2011-04-346759 · Cited by 67
Self-citationHeaton, K. M., Ju, G., & Grimm, E. A. (1993) · PubMed · Cited by 67
Young, P. A., Morrison, S. L., & Timmerman, J. M. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.08.002 · Cited by 66
Valkenburg, S. A., Li, O. T. W., Mak, P. W. Y., Mok, C. K. P., Nicholls, J. M., Guan, Y., Waldmann, T. A., Peiris, M. J. S., Perera, L. P., & Poon, L. L. M. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1403684111 · Cited by 62
Self-citationRoberti, M. P., Barrio, M. M., Bravo, A. I., Rocca, Y. S., Arriaga, J. M., Bianchini, M., Mordoh, J., & Levy, E. M. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1360-2 · Cited by 51
Zhang, M., Ju, W., Yao, Z., Yu, P., Wei, B., Simpson, R. J., Waitz, R., Fassò, M., Allison, J. P., & Waldmann, T. A. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1102604 · Cited by 49
Self-citationCombination therapy with interleukin-2 and antitumor monoclonal antibodies.
Sondel, P. M., & Hank, J. A. (1997) · PubMed · Cited by 46
Soiffer, R. J., Murray, C., Shapiro, C. L., Collins, H., Chartier, S., Lazo, S., & Ritz, J. (1996) · PubMed · Cited by 39
Highly potent anti-CD20-RLI immunocytokine targeting established human B lymphoma in SCID mouse
Vincent, M., Teppaz, G., Lajoie, L., Solé-Jamault, V., Bessard, A., Maillasson, M., Loisel, S., Béchard, D., Clemenceau, B., Thibault, G., et al. (2014) · mAbs · doi:10.4161/mabs.28699 · Cited by 38
Modest effect of interferon alfa on metastatic renal-cell carcinoma
Amato, R. J. (1999) · The Lancet · doi:10.1016/s0140-6736(05)74876-5 · Cited by 36
Brideau-Andersen, A. D., Huang, X., Sun, S.-C. C., Chen, T. T., Stark, D. M., Sas, I. J., Zadik, L., Dawes, G. N., Guptill, D. R., McCord, R., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609001104 · Cited by 35
Immunomodulatory and antitumor effects of interleukin-21 in patients with renal cell carcinoma
Curti, B. D. (2006) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.6.6.905 · Cited by 34
Merkel, T. J., Perera, P., Kelly, V. K., Verma, A., Llewellyn, Z. N., Waldmann, T. A., Mosca, J. D., & Perera, L. P. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1013083107 · Cited by 30
Self-citationCytokine treatment in cancer immunotherapy
Ardolino, M., Hsu, J., & Raulet, D. H. (2015) · Oncotarget · doi:10.18632/oncotarget.5095 · Cited by 26
Immunotherapy of advanced renal cell carcinoma: Current and future therapies
Gill, D. M., Hahn, A. W., Sonpavde, G., & Agarwal, N. (2016) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2016.1212794 · Cited by 13
Cited by
Inflammation and tumor progression: signaling pathways and targeted intervention
Zhao, H., Wu, L., Yan, G., Chen, Y., Zhou, M., Wu, Y., & Li, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00658-5 · Cited by 2,792
Targeting cytokine and chemokine signaling pathways for cancer therapy
Yi, M., Li, T., Niu, M., Zhang, H., Wu, Y., Wu, K., & Dai, Z. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01868-3 · Cited by 455
Current and emerging therapeutic approaches for colorectal cancer: A comprehensive review
Kumar, A., Gautam, V., Sandhu, A., Rawat, K., Sharma, A., & Saha, L. (2023) · World Journal of Gastrointestinal Surgery · doi:10.4240/wjgs.v15.i4.495 · Cited by 272
Choi, Y., & Jung, K. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01114-w · Cited by 188
Singh, V. K., & Seed, T. M. (2021) · International Journal of Radiation Biology · doi:10.1080/09553002.2021.1969054 · Cited by 88
Metadata
- Authors
- Conlon, K. C., Miljkovic, M. D., & Waldmann, T. A.
- Venue
- Journal of Interferon & Cytokine Research
- Publisher
- SAGE Publications
- Published
- 2019-01
- Volume
- 39
- Issue
- 1
- Pages
- 6-21
- ISSN
- 1079-9907 (ISSN-L)
- 1557-7465
- OpenAlex
- W2807864393
- Cited by
- 518
- References
- 121
- FWCI
- 11.21
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.